Patients treated with enfortumab vedotin for advanced urothelial carcinoma (aUC), who had baseline neuropathy or diabetes mellitus “did not appear to have inferior outcomes,” according to an analysis of the multi-site, retrospective UNITE study. The researchers evaluated the efficacy of enfortumab vedotin, both in combination with pembrolizumab and as a monotherapy, for patients with neuropathy or diabetes mellitus, as many patients with those comorbidities were not included in landmark trials of enfortumab vedotin. The researchers hypothesized that no significant difference would be found ...